Clinical trial · Observational
"Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer" (THERRES)
"Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer"
NCT05051423CI-TRIAL-00054191THERRESunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main aim was to assess the tumor vascular perfusion pattern in gastric cancer (GC). The investigators used dynamic contrast harmonic imaging endoscopic ultrasound (CHI-EUS) and the results were compared with the immunohistochemical expression of CD105 and clinico-pathological parameters.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endoscopic ultrasound | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients diagnosed with primary gastric tumors referred to our department for EUS local staging.
- description
- Patients will be included or excluded according to the following criteria used throughout the study: * Inclusion criteria: Patients diagnosed with primary gastric tumors referred for local staging by EUS (n=40); Age 18 to 90 years old, men or women; Signed informed consent for EUS with contrast-enhancement and tissue sampling * Exclusion criteria: Prior treatment with chemo-radiotherapy; Failure to provide informed consent; severe coagulopathy. Data collected for each participant will include: Personal data (name, surname, age, sex); results from previous investigations (blood count, liver and renal function tests, tumoral markers, gastroscopy, computed tomography), EUS variables (including CEH-EUS), histological and immunohistochemical findings, TNM and pTNM status (if possible), molecular analysis findings.
- interventionNames
- Diagnostic Test: Endoscopic ultrasound
Primary outcomes (1)
- measure
- Correlations with statistical significance between time-intensity curve analysis parameters, immunohistochemical markers of angiogenesis and clinico-pathological parameters.
- timeFrame
- 1 year
- description
- The investigators expect to see correlations with statistical significance between immunohistochemical markers of angiogenesis (CD105), clinico-pathological and time-intensity curve (TIC) parameters :peak enhancement (PE), wash-in area under the curve (WiAUC), rise time (RT), mean transit time (mTTI), time to peak (TTP), wash-in rate (WiR), wash-in perfusion index (WiPI), wash-outAUC (WoAUC) and wash-in and wash-outAUC (WiWoAUC), fall time (FT), wash-out rate (WoR), quality of fit (QOF), region of interest area (ROI area).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with primary gastric adenocarcinoma; * no neoadjuvant therapy; * age: 18 to 90 years old; * gender: men or women; * signed informed consent for EUS with contrast-enhancement and tissue sampling; Exclusion Criteria: * other types of gastric cancer than adenocarcinoma; * prior treatment with chemo-radiotherapy; * failure to provide informed consent; * severe coagulopathy.
References
Publications (10)
- BACKGROUNDFolkman J. Fundamental concepts of the angiogenic process. Curr Mol Med. 2003 Nov;3(7):643-51. doi: 10.2174/1566524033479465. PMID 14601638
- BACKGROUNDKerbel RS. Tumor angiogenesis. N Engl J Med. 2008 May 8;358(19):2039-49. doi: 10.1056/NEJMra0706596. No abstract available. PMID 18463380
- BACKGROUNDShibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006 Mar 10;312(5):549-60. doi: 10.1016/j.yexcr.2005.11.012. Epub 2005 Dec 5. PMID 16336962
- BACKGROUNDSmith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jurgensmeier JM, Womack C. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res. 2010 Jul 15;16(14):3548-61. doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6. PMID 20606037
- BACKGROUNDLi L, Wang L, Song P, Geng X, Liang X, Zhou M, Wang Y, Chen C, Jia J, Zeng J. Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis. Mol Cancer. 2014 Apr 9;13:81. doi: 10.1186/1476-4598-13-81. PMID 24716659
- BACKGROUNDFerrara N. Vascular endothelial growth factor. Eur J Cancer. 1996 Dec;32A(14):2413-22. doi: 10.1016/s0959-8049(96)00387-5. No abstract available. PMID 9059329
- BACKGROUNDUlyatt C, Walker J, Ponnambalam S. Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochem Biophys Res Commun. 2011 Jan 21;404(3):774-9. doi: 10.1016/j.bbrc.2010.12.057. Epub 2010 Dec 17. PMID 21168388
- BACKGROUNDChen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ, Lee PH. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett. 2004 Sep 15;213(1):73-82. doi: 10.1016/j.canlet.2004.05.020.